abbott china
Abbott China (雅培中国), a subsidiary of Abbott Laboratories (NYSE: ABT), distributes cardiovascular devices, FreeStyle Libre continuous glucose monitoring, diagnostics, established pharmaceuticals, and nutrition products to Chinese hospitals, medical specialists, and consumer patients via direct, pharmacy, and digital channels.
- Company typePublic
- Founded1995
- Headquarters—
- Headcount5,001–10,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What abbott china does
Abbott China (雅培中国) is the Chinese operating subsidiary of U.S.-listed Abbott Laboratories (NYSE: ABT), operating as 雅培贸易（上海）有限公司 (Abbott Trading (Shanghai) Co., Ltd.) with 5,001-10,000 employees. It distributes and markets a diversified healthcare portfolio across five core technology platforms: cardiovascular devices (coronary and peripheral vascular stents, pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy, structural heart closure devices, 3D mapping and ablation systems, remote monitoring); continuous glucose monitoring under the FreeStyle Libre brand spanning first-generation and FreeStyle Libre 2 personal sensors plus a hospital-grade CGM system; diagnostics including the i-STAT handheld blood analyzer, ID NOW rapid molecular platform, and clinical chemistry/immunochemistry assays; established pharmaceuticals covering hepatology, gastroenterology, cardiology, neurology, gynecology, respiratory and urology; and neuromodulation (Proclaim XR and Eon Mini spinal cord stimulators, Infinity deep brain stimulation system for Parkinson's disease, epilepsy, and essential tremor). A consumer nutrition franchise under Ensure and Glucerna brands rounds out the portfolio.
The company serves two primary end markets: institutional healthcare (hospitals, clinics, medical specialists across vascular surgery, cardiology, endocrinology, and neurology) and consumer patients with chronic conditions such as diabetes, requiring glucose monitoring and nutritional support. Abbott China operates a hybrid go-to-market combining a direct enterprise sales force serving hospitals and procurement systems, professional medical channel distribution for prescription pharmaceuticals, pharmacy and retail distribution for consumer nutrition and self-monitoring devices, and direct-to-consumer availability for products like FreeStyle Libre. Revenue is generated through hardware sales (devices and sensors) and product sales (pharmaceuticals and nutrition) priced via negotiated hospital procurement and pharmacy channels; specific pricing is not publicly disclosed. The subsidiary has been awarded 'Top Employer China' certification for 15 consecutive years through 2026, a marker of sustained operational presence, and continues to invest in medical education, disease awareness campaigns (notably the 2026 peripheral vascular health initiative with leading vascular surgeons), and recurring CIIE participation.
abbott china firmographics
Firmographics- Name
- abbott china
- Legal name
- 雅培贸易（上海）有限公司
- Website
- https://abbott.com.cn
- Company type
- Public
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Abbott China (雅培中国), a subsidiary of Abbott Laboratories (NYSE: ABT), distributes cardiovascular devices, FreeStyle Libre continuous glucose monitoring, diagnostics, established pharmaceuticals, and nutrition products to Chinese hospitals, medical specialists, and consumer patients via direct, pharmacy, and digital channels.
- Ownership category
- akta.pro rank
abbott china industry classification
Industry- Product category
- Medical Devices and Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
- akta.pro secondary industries
- Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE), Specialty Care Pharmaceuticals (HLAIAAAB), Medical & Clinical Nutrition Beverage Production (Oral Nutritional Supplements) (AFAFAFAJ)
Keywords
abbott china business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Medical Devices and Diagnostics: Revenue from cardiovascular devices (stents, pacemakers, structural heart), diagnostic equipment (laboratory systems, point-of-care), and neuromodulation implants sold to hospitals and healthcare providers.
- Established Pharmaceuticals: Revenue from mature prescription pharmaceuticals covering digestive, cardiovascular, neurological, respiratory, gynecological, and hepatic therapeutic areas, distributed through medical and pharmacy channels.
- Nutritional Products: Revenue from scientific nutrition products including complete nutrition supplements (Ensure), diabetes-specific nutrition (Glucerna), and specialized medical nutrition for various patient populations.
- Consumer Self-Testing Products: Revenue from consumer-facing products like FreeStyle Libre for personal blood glucose monitoring, sold through pharmacies and directly to consumers.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
abbott china product offering
Product offeringCore offering
Abbott China develops, manufactures, and distributes a diversified portfolio of medical devices (cardiovascular stents, pacemakers, ICDs, CRT devices, neuromodulation implants), in vitro and point-of-care diagnostic systems, established prescription pharmaceuticals across digestive, cardiovascular, neurological, respiratory, and hepatic therapeutic areas, and scientific/clinical nutritional products. It markets directly to hospitals and medical professionals through a professional sales force, and reaches consumers through retail pharmacies and direct channels for nutrition supplements (Ensure, Glucerna) and the FreeStyle Libre continuous glucose monitoring system.
Product overview
Abbott China operates as a diversified healthcare company organized across five major business segments: (1) Cardiovascular Technologies — covering coronary and peripheral vascular interventions, cardiac rhythm management (pacemakers, ICDs, leads), heart failure devices (CRT), structural heart (left atrial appendage closure, mechanical/bioprosthetic valves, annuloplasty rings), remote monitoring, and 3D cardiac mapping/ablation systems; (2) Diabetes Care — anchored by the FreeStyle Libre continuous glucose monitoring (CGM) platform comprising FreeStyle Libre 1 and 2 generations for personal use, plus hospital-grade CGM and blood/beta-ketone meters; (3) Diagnostics — spanning clinical chemistry/immunochemistry, hematology, molecular automation, point-of-care i-STAT, and rapid molecular ID NOW platforms; (4) Established Pharmaceuticals — covering digestive (Creon, Domperidone, otilonium bromide, lactulose), gynecological (Femoston, Duphaston), cardiovascular (fenofibrate, metoprolol, amiodarone, propafenone), neurological (Levomargin), respiratory (clarithromycin), urinary (terazosin), and hepatology (ademetionine/Transmetil) products; (5) Neuromodulation — featuring the Proclaim XR and Eon Mini implantable spinal cord stimulation (SCS) systems for chronic pain, and the Infinity deep brain stimulation (DBS) system for movement disorders (Parkinson's, tremor, epilepsy). The portfolio spans consumer-facing nutritional products (Ensure Complete, Glucerna SR) alongside professional medical devices and prescription pharmaceuticals.
Differentiator
Problem solved
Functional benefit
Brands
- FreeStyle Libre (辅理善瞬感): Continuous glucose monitoring system for diabetes management
- Ensure (雅培全安素)
- Glucerna (雅培益力佳)
- Proclaim XR
- Infinity DBS
Products and services
- FreeStyle Libre 2 (雅培瞬感 2 代) Continuous Glucose Monitoring System Second-generation continuous glucose monitoring (CGM) system for personal use that enables patients to monitor glucose levels continuously without routine finger pricks, with real-time glucose readings and alarms transmitted via smartphone integration.
- FreeStyle Libre (雅培瞬感 1 代) Continuous Glucose Monitoring System First-generation continuous glucose monitoring system for personal use, providing ambulatory glucose monitoring with factory-calibrated sensor technology.
- Ensure Complete (雅培全安素) Complete nutritional formula available in vanilla and wheat flavors, serving as a medical nutrition product and health foundation for recovery and daily nutritional supplementation.
- Glucerna SR (雅培益力佳SR) Specialized nutrition product for individuals with elevated blood glucose, designed to help manage blood sugar as part of diabetes dietary management.
- Proclaim XR Recharge-free Implantable Spinal Cord Stimulator Rechargeable implantable spinal cord stimulation (SCS) system for the treatment of chronic pain and movement disorders, featuring a wireless platform and software integration for personalized therapy.
- Infinity Deep Brain Stimulation System (Infinity DBS) Deep brain stimulation system that delivers electrical pulses to specific brain targets controlling motor function for treatment of Parkinson's disease, epilepsy, and essential tremor. FDA approved for Parkinson's disease since 2002; uses a wireless platform and software for personalized treatment.
- Implantable Pacemakers, ICDs and Pacing Leads Implantable cardiac pacemakers, implantable cardioverter defibrillators (ICDs), and pacing leads for cardiac rhythm management and treatment of arrhythmias.
- Cardiac Resynchronization Therapy Devices (CRT-P / CRT-D) Cardiac resynchronization therapy devices including biventricular pacemakers (CRT-P) and CRT defibrillators (CRT-D) for the treatment of heart failure.
- i-STAT Point-of-Care Diagnostic System Point-of-care diagnostic platform enabling rapid blood testing for a range of parameters at the bedside or in clinical settings.
- ID NOW Rapid Diagnostic System Rapid molecular diagnostic platform for infectious disease testing with fast turnaround time.
- Transmetil (思美泰) Ademetionine 1,4-Butanedisulfonate Hepatology pharmaceutical product with mechanisms including hepatocyte membrane improvement, detoxification, antioxidant effects, and promotion of liver cell regeneration; available in injectable and enteric-coated tablet forms.
- Ensure (安素) Enteral Nutrition Powder (TP) Enteral nutrition powder for oral or tube feeding in patients requiring nutritional support.
Quantifiable outcome
- FreeStyle Libre has transformed glucose monitoring by eliminating routine finger pricks
- +1 more outcomes
Companies that use abbott china
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
abbott china technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
abbott china partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Chinese Vascular Surgery Experts and SpecialistscoreAbbott China partnered with leading vascular surgery experts nationwide for the '足够健康 脉向未来' (Healthy Feet, Future Pulse) peripheral vascular disease awareness campaign. The initiative, launched in Beijing on May 24, 2026, aims to raise public awareness about peripheral vascular disease and improve disease recognition and treatment standards.
Scale indicators1 record
Recent moves4 records
Expansion highlights4 records
abbott china competitors and assessment
Company assessmentDirect peers
- Siemens Healthineers China: Major competitor in the China diagnostics market, particularly in laboratory diagnostics, clinical chemistry, immunoassay, and point-of-care testing where Abbott's i-STAT, ID NOW, and immunochemistry platforms compete for the same hospital lab customers.
- Medtronic China: China subsidiary of Medtronic plc; directly competes with Abbott China across cardiovascular devices, cardiac rhythm management, neuromodulation (DBS and SCS), and diabetes care, addressing the same hospital customers and patient populations.
- Boston Scientific China: Operates a China business directly competing with Abbott in interventional cardiology, structural heart, cardiac rhythm management, and peripheral vascular intervention products sold to the same hospital channel.
- Becton Dickinson China: Operates a substantial China medical device business including diagnostic systems, biosciences, and medication delivery solutions, with overlap to Abbott in point-of-care diagnostics and clinical laboratory products.
- Roche Diagnostics China: Leading diagnostics competitor in China with overlapping portfolios in clinical chemistry, immunoassays, molecular diagnostics, and centralized laboratory automation that compete head-to-head with Abbott's diagnostics business.
Emerging players
- MicroPort Scientific: Shanghai-headquartered medical device group directly competing with Abbott China in coronary and peripheral vascular stents, structural heart, and cardiac rhythm management, with strong local procurement advantages in China.
- Mindray: Leading Chinese medical device manufacturer competing with Abbott China in patient monitoring, in-vitro diagnostics, and increasingly in cardiovascular and life-science instruments, with growing domestic-preference advantage in hospital tenders.
Broad incumbents
- Stryker China: Global medical device incumbent operating in China across surgical equipment, neurotechnology, and orthopedic/spine segments; comparable as a multinational device seller targeting the same hospital procurement channels as Abbott China.
- Philips Healthcare China: Broad multinational healthcare technology player in China competing with Abbott across patient monitoring, diagnostic imaging, and connected care solutions sold into the same hospital networks.
- Johnson & Johnson Medical China: Broad multinational healthcare incumbent in China with overlapping capabilities in cardiovascular intervention (Biosense Webster electrophysiology), surgical devices, orthopedics, and vision care — overlapping with several Abbott China franchises as part of a wider portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
abbott china social profiles
Digital presenceabbott china financial estimates
Financial estimateRevenue estimate
Valuation estimate
abbott china leadership team
Management profileNumber of profiles
abbott china funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
abbott china M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about abbott china
What does abbott china do?
Abbott China develops, manufactures, and distributes a diversified portfolio of medical devices (cardiovascular stents, pacemakers, ICDs, CRT devices, neuromodulation implants), in vitro and point-of-care diagnostic systems, established prescription pharmaceuticals across digestive, cardiovascular, neurological, respiratory, and hepatic therapeutic areas, and scientific/clinical nutritional products. It markets directly to hospitals and medical professionals through a professional sales force, and reaches consumers through retail pharmacies and direct channels for nutrition supplements (Ensure, Glucerna) and the FreeStyle Libre continuous glucose monitoring system.
Is abbott china a public or private company?
abbott china is a public company. It is classified as corporate owned and is currently operating.
When was abbott china founded?
abbott china was founded in 1995. It employs 5,001 to 10,000 people.
How does abbott china make money?
Four revenue lines are on record. Medical Devices and Diagnostics are the primary driver. The others are established Pharmaceuticals, nutritional Products and consumer Self-Testing Products.
Who are abbott china's main competitors?
Direct peers on record are Siemens Healthineers China, Medtronic China, Boston Scientific China, Becton Dickinson China and Roche Diagnostics China. Emerging players are MicroPort Scientific and Mindray. Broad incumbents are Stryker China, Philips Healthcare China and Johnson & Johnson Medical China.
Does abbott china have an API?
No public API is recorded for abbott china.
What industry is abbott china in?
abbott china's product category is Medical Devices and Diagnostics. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAHAE, Insulin Pen Needles, Syringes & Infusion Sets (Consumables). Its NAICS code is 334510 and its SIC code is 3841.